<DOC>
	<DOCNO>NCT00080990</DOCNO>
	<brief_summary>This phase I trial study side effect best dose alvocidib give together oxaliplatin , fluorouracil , leucovorin calcium treat patient advance solid tumor . Drugs use chemotherapy , alvocidib , oxaliplatin , fluorouracil , leucovorin calcium , work different way stop tumor cell divide stop grow die . Alvocidib may also make tumor cell sensitive chemotherapy . Combining one chemotherapy drug may kill tumor cell .</brief_summary>
	<brief_title>Alvocidib , Oxaliplatin , Fluorouracil , Leucovorin Calcium Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose flavopiridol give combination oxaliplatin , fluorouracil , leucovorin calcium patient advance solid tumor . II . Determine pharmacokinetics regimen patient . III . Determine , preliminarily , therapeutic activity regimen patient . IV . Determine dose-limiting toxicity recommend phase II dose flavopiridol administer regimen patient . V. Determine safety tolerability regimen patient . VI . Correlate p21 , p53 , apoptotic marker response patient treat regimen . OUTLINE : This non-randomized , open-label , dose-escalation study flavopiridol . Patients receive alvocidib intravenously ( IV ) 1 hour , oxaliplatin IV 2 hour , leucovorin calcium IV 2 hour , fluorouracil IV continuously 48 hour day 1 , 15 , 29 . Courses repeat every 42 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos alvocidib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , cohort expand additional 10 patient treat dose .</detailed_description>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histologically confirm advanced solid tumor Refractory standard therapy standard therapy exist Evaluable disease No known untreated CNS metastasis Patients undergone local treatment brain metastasis whose brain metastases stable repeat image study perform ≤ 4 week treatment allow No primary CNS tumor Performance status Karnofsky 60100 % WBC ≥ 3,500/mm^3 Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis ) Creatinine ≤ 1.5 mg/dL No cardiac arrhythmia within past 6 month No congestive heart failure within past 6 month No myocardial infarction within past 6 month No arterial venous thrombosis within past year No peripheral neuropathy &gt; grade 1 No medical condition would preclude study participation No serious uncontrolled infection HIV negative Not pregnant nursing No nursing 2 month study participation Negative pregnancy test Fertile patient must use effective contraception 2 month study participation At least 2 week since prior immunotherapy At least 2 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No prior flavopiridol At least 2 week since prior radiotherapy Recovered prior therapy No concurrent therapy thrombosis Prophylaxis central line deep vein thrombosis allow No concurrent investigational medication No concurrent vitamin , antioxidant , herbal preparation supplement Concurrent singletablet multivitamin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>